軟組織異體移植片的全球市場 - 成長,趨勢,預測(2019年∼2024年)

Soft Tissue Allografts Market - Growth, Trends, Covid-19 Impact, and Forecasts (2021 - 2026)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 111 Pages | 商品交期: 2-3個工作天內



  • 全貌
  • 簡介
  • 目錄




第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 老年人的增加
    • 田徑運動以及其他運動的軟組織異體移植片的需求增加
    • 軟組織置換技術的進步
  • 市場阻礙因素
    • 治療費高
    • 複雜的償付制度
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第5章 市場區隔

  • 各類型
    • 軟骨異體移植片
    • 肌腱異體移植片
    • 半月軟骨異體移植片
    • 牙科異體移植片
    • 其他
  • 各用途
    • 整形外科
    • 牙科
    • 創傷護理
    • 其他
  • 各終端用戶
    • 醫院
    • 審美中心
    • 整形外科
    • 牙科醫院
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Allergan Plc
    • B. Braun Melsungen AG
    • Conmed Corporation
    • Xtant Medical Holdings, Inc.
    • Alliqua BioMedical, Inc.
    • AlonSource Group
    • Becton Dickinson and Company
    • Arthrex, Inc.
    • Bone Bank Allografts
    • Osiris Therapeutics, Inc.
    • Integra LifeSciences Corporation
    • Stryker Corporation

第7章 市場機會及未來趨勢

Product Code: 62796

The Soft Tissue Allografts Market was valued at USD 3,077.43 million in 2020, and it is expected to reach USD 4,724.46 million by 2026, registering a CAGR of 6.75% during the period of 2021-2026.

The outbreak of COVID-19 resulted in decreased public mobility and significantly impacted the therapeutic and surgical procedures, as the surgical procedures that are non-immediate and are being postponed to decrease the burden on healthcare infrastructure.

The outbreak of COVID-19 worldwide showed an impact on the market studied as surgical procedures kept on hold in order to prevent the spread of the COVID-19 virus. There is tremendous pressure on the hospitals and other healthcare centers in providing services to COVID-19 patients is also one of the factors that are inhibiting the hospitals in providing services.

The rising demand for soft tissue allografts in athletics and other sports is contributing largely to the market growth. Modern training regimens in athletics, field events, and a number of other contact sports like American football, require athletes to undergo intensive training sessions which are in practice more strenuous than the actual sport itself.

High-intensity training regimens are directly correlated with athletic performance improvement but excessive training also induces muscle and bone fatigue and often leads to injury. Consequently, injury prevalence among athletes has been increasing especially due to excessive training. The competitive nature of sports has spurred the demand among athletes for quick recovery and easily accessible modalities to treat musculoskeletal injuries.

Furthermore, osteoarthritis has a considerable impact on the individual patient, resulting in pain & disability, and the increasing prevalence of this diseases is expected to boost the market in near future.

For instance, as per data from the U.S. Department of Health and Human Services, 2018 reports an estimated 8.6 million sports injuries occur each year. The soft tissue market finds its grip behind technology development. While many companies in the market would like to release products that help market growth, awareness and growth in learning levels about these products will also play a big role. The level of awareness among the public, especially with the increase in internet access and easy access to social media, has increased. Over time, the soft tissue market will benefit from growing knowledge about products and processes.

Thus, demand for soft tissue allografts has been increasing in athletics and other contact sports, which in turn is fuelling the growth of the global soft tissue allografts market.

Key Market Trends

Cartilage Allograft is Expected to Hold Significant Market Share Over the Forecast Period

Cartilage allografts are the vital components in orthopedic surgical procedures such as joint reconstruction etc. Cartilage graft transplantation is frequently used in the treatment of chondral and osteochondral lesions, most commonly in the knee. These procedures can serve to improve the quality of life for those with pathology of the cartilage within joints and alleviate symptoms.

According to Ann Med Surg in his article published in 2020, estimate of the orthopedic surgery cancellation rate was approximately 82.0%, representing 6,295,041 of 7,677,515 cases. They concluded that if countries increased their normal surgical volumes by 20% after the pandemic, it would take about 45 weeks to clear the backlog of operations resulting from the disruption caused by COVID-19.

The scientific basis of Osteochondral allograft (OCA) is the transplantation of fully developed, or mature hyaline (joint) cartilage containing living cartilage cells ('chondrocytes') that survive the transplant and support the production of the cartilage matrix indefinitely.

As per the 2019 article published on Journal of Bone & Joint Surgery, Inc. by the researchers from Ohio State University College of Medicine, the conclusion of the study demonstrated that Osteochondral allograft (OCA) transplantation is a versatile treatment option for patients with cartilage and osteochondral defects and it is a uniquely useful treatment option for patients with large high-grade osteochondral defects and for athletes who have substantial incentives to return to sport as quickly as possible.

Arthrex, Inc. is one of the most renowned company involved in development of cartilage allografts. The company's portfolio includes several cartilage allografts namely Arthrex Meniscal Allograft Arthroplasty, Small Joint OATS (Osteochondral Autograft Transfer System) amongst others.

In March 2019, MTF Biologics expanded its portfolio with the launch of CartiMax viable cartilage allograft. CartiMax is a putty-like cartilage allograft designed to easily fill lesions in the knee, foot and ankle.

Thus, owing to the aforementioned factors, the market for Cartilage allografts segment is expected to grow significantly during the forecast period.

North America is Expected to Dominate the Market Over the Forecast Period

In North America, the market growth is majorly driven by factors, such as increasing prevalence of diabetic foot ulcers, better healthcare awareness program for diabetes, and an increasing number of surgical procedures on anterior cruciate ligament (ACL).

During COVID-19 pandemic 2020, in North America region, the specialty clinics, including dental practices and hospitals were shut down or their operations were limited, and some hospitals were being converted to containment facilities and treatment wards for COVID-19 patients.

In March 2020, in the United States, National Association for the Advancement of Orthotics and Prosthetics (NAAOP) issued an alert in which it was made clear that during the COVID-19 national emergency, state and local health authorities should consider orthotic and prosthetic practices as essential providers that must remain accessible to patients in need of orthotic and prosthetic care.

According to the Canadian Institute for Health Information 2019 report, the number of Canadians having joint replacements has increased over the past 5 years, with 130,000 surgeries being performed annually. There were almost 59,000 hip replacements and more than 70,000 knee replacements that were performed in Canada in 2017-2018. This represents an increase of 17.4% and 17%, respectively, over the last 5 years.

Therefore, the rising burden of diseases is creating tremendous opportunities for market players, and they are focusing on R&D activities, in order to bring new & reliable products in the market, thus, driving the market growth. For instance, In Feb 2020, Integra LifeSciences Holding Corporation has made the launch of AmnioExcel Plus Placental Allograft Membrane, that is the latest wound care offering to support soft tissue repair. Thus, owing to the aforementioned factors the market is expected to witness a high growth rate, over the forecast period.

Competitive Landscape

The Soft Tissue Allografts Market is moderately competitive and many of the global players are into the market. Some of the market players include Abbvie inc. (Allergan), Conmed Corporation, Becton Dickinson and Company, Smith & Nephew (Osiris Therapeutics Inc.), Integra LifeSciences Corporation, Stryker Corporation, Zimmer Biomet, Arthrex Inc., Direct Biologics and others. Also, new product launches from these players are augmenting the demand for these products.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support



  • 1.1 Study Assumptions
  • 1.2 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Cases of Orthopedics and Dentistry Related with Aging
    • 4.2.2 Increasing Demand for Soft Tissue Allografts in Athletics and Other Sports
    • 4.2.3 Advancements in Soft Tissue Replacement
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Treatment
    • 4.3.2 Complicated Reimbursement and Regulatory Policies
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Type
    • 5.1.1 Cartilage Allograft
    • 5.1.2 Tendon Allograft
    • 5.1.3 Meniscus Allograft
    • 5.1.4 Dental Allograft
    • 5.1.5 Other Types
  • 5.2 By Application
    • 5.2.1 Orthopedic
    • 5.2.2 Dentistry
    • 5.2.3 Wound Care
    • 5.2.4 Other Applications
  • 5.3 By End-User
    • 5.3.1 Hospitals
    • 5.3.2 Aesthetic Centres
    • 5.3.3 Orthopedic Clinics
    • 5.3.4 Dental Clinics
    • 5.3.5 Other End Users
  • 5.4 Geography
    • 5.4.1 North America
      • United States
      • Canada
      • Mexico
    • 5.4.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.4.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • 5.4.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 Abbvie inc. (Allergan)
    • 6.1.2 Conmed Corporation
    • 6.1.3 Xtant Medical Holdings Inc.
    • 6.1.4 Bone Bank Allografts
    • 6.1.5 Smith & Nephew(Osiris Therapeutics Inc.)
    • 6.1.6 Integra LifeSciences Corporation
    • 6.1.7 Stryker Corporation
    • 6.1.8 Zimmer Biomet
    • 6.1.9 Arthrex Inc.
    • 6.1.10 Direct Biologics